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Totipotency, defined as the ability of a single cell to generate an entire individual, has traditionally
served as a cornerstone to frame the moral relevance of nascent human life. This ‘‘potentiality prin-
ciple’’ has served as an ethical reference point for shaping legal regulations for stem cell research in
most Western countries. Based on heterogeneous ethical, religious, and political views, different
countries cope with recent advances in mammalian cloning and reprogramming in a remarkably
diverse manner. This and related issues were key topics at a recent meeting held in Berlin, Germany,
on ethical aspects of stem cell research in Europe. An emerging view from this event is that interna-
tional heterogeneity in stem cell politics and legislation must be overcome in order to develop this
field toward biomedical application.The workshop ‘‘Ethical Aspects of Stem Cell Research in
Europe,’’ held April 19–20, 2007, in Berlin, was a joint effort
of EuroStemCell and ESTOOLS, two large multinational
research consortia funded by the 6th framework program
of the European Commission (EC), and coordinated by
Austin Smith (University of Cambridge, UK) and Peter
Andrews (University of Sheffield, UK), respectively. In
addition to projects focusing on stem cell biology, both
consortia include work packages dedicated to ethics
and societal issues related to stem cell research. These
ethics projects are led by Goran Hermeren from Lund Uni-
versity, who was also one of the workshop organizers. The
meeting brought together ethicists, philosophers, stem
cell biologists, clinicians, biotech entrepreneurs, EC
representatives, and politicians from all over Europe to
confront controversial aspects of legislation on stem cell
research, to evaluate the feasibility of stem cell-based
therapies, and to define potential milestones for a road
map toward clinical application. This report discusses
the key scientific, ethical, and legal issues, with a particular
focus on (1) the impact of the latest advances in cellular re-
programming on the concept of cell potency and (2) the
regulatory challenges for translational stem cell research.
No Longer a Matter of Debate: The Need
for Pluripotent Cells
In the past, discussions about stem cell research typically
centered around the question of whether embryonic stem
cells (ESCs) or somatic (‘‘adult’’) stem cells represent the
most suitable candidates for cell replacement therapies
and other biomedical applications. Indeed, both types of
stem cells feature unique properties and yielded an im-
pressive series of recent advances. However, at the meet-
ing it became clear once again that the initial enthusiasm
about an alleged transdifferentiation of adult stem cellshas given way to a more realistic perspective, i.e., using
adult stem and progenitor cells for repairing their tissue
of origin.
The therapeutic potential of adult stem cells was high-
lighted by impressive work on Duchenne muscular dystro-
phy that was presented by Giulio Cossu from the San
Raffaele Scientific Institute in Milano. Pediatric patients
afflicted with this still untreatable disease typically be-
come wheelchair bound by their early teens and die in their
early 20s due to respiratory insufficiency. Cossu and his
colleagues succeeded in deriving and expanding a canine
vessel-derived stem cell termed mesangioblast, which
restored motility when injected intra-arterially into dystro-
phic dogs (Sampaolesi et al., 2006). Only a few months
later, the Cossu team isolated the same stem cells from
human donors, including pediatric Duchenne patients.
The cells could be engineered to express human minidy-
strophin and were shown to colonize skeletal muscle of
dystrophic immunodeficient mice (Dellavalle et al.,
2007). This work provides perspectives to use either
heterologous HLA-matched cells from healthy donors or
autologous, gene-corrected cells from Duchenne patients
for first clinical trials.
Already advanced into transition to a clinical application
are Yann Barrandon and his colleagues from the Ecole
Polytechnique Fe´de´rale de Lausanne, who make use of
ex vivo expanded autologous keratinocytes for transplan-
tation in third-degree burn wounds. This life-saving treat-
ment has been shown to restore essential barrier functions
of the skin and result in a normal epidermis being func-
tional for many years.
While these studies show how close adult stem cell re-
search has come to clinical application, it is fair to note
that recent excitement about these cells was not as
much fueled by the idea of tissue-specific repair but ratherCell Stem Cell 1, August 2007 ª2007 Elsevier Inc. 153
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for a large variety of cell types. Core of this concept was
the idea to use adult stem cells from regenerative tissues
such as bone marrow to generate cells of nonregenerative
tissues such as nervous system, heart, or insulin-produc-
ing cells. With sound evidence supporting ‘‘transdifferen-
tiation’’ into functional neurons, cardiomyocytes, and
b cells still lacking, the adult stem cell field is experiencing
a sobering yet healthy period of refocusing.
Notwithstanding recent evidence from rodent studies
suggesting that stem cells in the adult brain can give rise
to new neurons (Thored et al., 2006), Olle Lindvall (Lund
University), a pioneer in the field of neural transplantation,
pointed out that it is unclear to what extent the endoge-
nous adult stem cell source can be tapped and exploited
for clinical purposes. For the time being, Lindvall stresses,
ESCs provide the most versatile exogenous donor source
for neural replacement. Indeed, the potential of pluripotent
ESCs for the in vitro generation of nonregenerative cell
types is increasingly recognized.
The Rush for Alternatives: Loophole Science
and True Breakthroughs
Ever since ESCs entered the public debate, the derivation
of these unique cells from the early embryo spurred moral
concerns and fueled an at times misguided quest for less
ethically controversial alternatives. Transdifferentiation
hype and multipotent adult progenitor cells with ESC-
like plasticity provided the first wave. ‘‘From blood to
brain’’ and the like were frequent slogans in these days.
Envisioning the potential to generate diverse somatic cells
from the patient to be treated, these reports also tackled
the problem of immune rejection of allogeneic cells. Advo-
cates for pluripotent stem cells responded with the vision
of therapeutic cloning, building on Campbell and Wilmut’s
seminal work. However, as first exemplified by the sheep
Dolly, somatic nuclear transfer (SNT) into enucleated oo-
cytes yields totipotent cells, which, in terms of potentiality,
represent an embryo equivalent. In addition, translation
into a clinical realm would require large numbers of do-
nated oocytes, which constitutes an ethical problem of
its own, as underlined by Anne McLaren from the Well-
come Trust Gurdon Institute in Cambridge (see also
McLaren [2007]).
The controversy spurred a remarkable and unprece-
dented series of studies aimed at circumventing these
sensitive points. Cell fusion, which originally brought
down the concept of transdifferentiation, was now turned
into an avant-garde technology for transferring pluripo-
tency from ESCs to somatic cells. And while the
tetraploidy of the resulting cells remains an issue, this
area of research is likely to provide a wealth of data on
reprogramming mechanisms. Other scientists aim at dis-
engaging totipotency. Conditional inactivation of cdx2,
for example, prevents trophoblast differentiation of a
cloned cell, thus excluding implantation and further devel-
opment (Meissner and Jaenisch, 2006). ‘‘Do no harm’’ was
the credo of others, culminating in studies on human blas-
tomere-derived ESCs (Klimanskaya et al., 2006). Since154 Cell Stem Cell 1, August 2007 ª2007 Elsevier Inc.preimplantation diagnosis has shown that single blasto-
meres can be removed without incapacitating the embryo,
this strategy was proposed as an ethically acceptable
route to derive human ESCs. Loophole science? Davor
Solter, from the Max Planck Institute for Immunobiology,
argued that at least some of these studies might be con-
fronted with the question of whether they would have
ever been conducted for purely scientific reasons. And in
any case, none of these attempts seem to have really
solved the deepest ethical concerns. For example, in the
case of altered nuclear transfer based on cdx2 ablation,
the scientifically and morally challenging question has
been posed of whether a cdx2-deficient clone is an em-
bryo that died when it needed cdx2, or a purely artificial
entity that never started to live in the first place. This brings
us back to biological potency, one of the central themes of
the meeting.
Potentiality and Reprogramming
In a nutshell, the potentiality argument as applied in the
context of hESC research mandates that, since a zygote
has the potential to become a person, it is warranted to
treat it as if it were already a person, and hence that it is
wrong to use it for the derivation of hESCs no matter
what potential benefits they may entail. It is important to
scrutinize the validity of this claim because several legisla-
tions in Europe are based, more or less explicitly, on the
potentiality argument. Germany is a paradigmatic exam-
ple: the embryo protection law states that an embryo
(the object of the law’s protection) is a fertilized zygote,
as is every totipotent cell separated from it. Hence, as
further sustained by Ludger Honnefelder (Institute of
Science and Ethics, University of Bonn), it becomes a crim-
inal act to use totipotent cells for cell derivation or any other
intervention, which is not to the benefit of the embryo.
Now, sustained bioethical scrutiny had done away with
the potentiality principle a long time ago, demonstrating
that it is a prime example of non sequitur: if A has the po-
tential to become B, it does not follow that we can or in fact
should treat it as if it were already B. We may decide to
treat B as if it were A, and we may even show good rea-
sons for doing it, but we cannot consider this decision
as the only possible logical conclusion since it is simply
a political act. As such, it cannot be just taken at face value
and needs to be justified, on a par with all political acts.
The importance of this conclusion is general and lies not
so much in the fact that it debunks the potentiality
argument per se as in the way in which it shows how reg-
ulations can no longer be justified as emanating directly
from ‘‘facts,’’ be they moral or biological facts. In other
words, when we recognize that the fact that the zygote
is totipotent does not logically or necessarily imply that
we should treat it as a person, we also recognize some-
thing much more general, namely that laws and regula-
tions are primarily social constructions, even or especially
when, as in the case of natural law, they purport to act
neutrally as repositories of naturally encoded notions of
good and bad. But if this is true, why then are we still deal-
ing with the potentiality principle, and why do many
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around the life sciences? On this issue, the Berlin meeting
provided some key insights. The point is that, whereas
bioethical reasoning had long dismissed the validity of
the potentiality argument, science still seemed to provide,
until a few years ago, a set of reasonable boundaries to
treat cell potency as if it were a natural given. But the birth
and life of Dolly, along with the flurry of research on ge-
nome reprogramming, have since demonstrated how
fragile and ultimately inadequate the concept of potency
is to inspire public policy (Stanton and Harris, 2005). As
Hans Scho¨ler from the Max Planck Institute for Molecular
Biomedicine and Giuseppe Testa from the European Insti-
tute of Oncology pointed out, potency without context
means nothing. In many ways, this had always been
true: the IVF zygote, totipotent in abstract terms, still
needs a woman and her womb in order to deploy its po-
tency. But the latest advances in genome reprogramming
research, on the wave of last year’s seminal paper by Ya-
manaka, make this point even more vivid. The work
showed that overexpression of a defined combination of
genes can turn fibroblasts into ES-like cells (Takahashi
and Yamanaka, 2006). Three new papers now extend
these findings, showing, among other data, that such in-
duced pluripotent stem cells (iPS cells) are germline com-
petent and, after injection into tetraploid blastocysts, can
even generate purely iPS cell-derived embryos (Maherali
et al., 2007; Okita et al., 2007; Wernig et al., 2007). The
overall conclusion is that potency is best understood as
a fluent state, which can be initiated in any cell through
the steering of selected gene networks. In this sense, it
is indeed an ironic twist of fate that the research efforts
aimed at reprogramming adult cells in order to bypass
the perceived ethical problems of ES cells end up disman-
tling the very argument most of those ethical problems
were based on. For if we were serious about the potential-
ity principle, we would, in the not-too-distant future, also
have to prohibit the use of artificial but totipotent deriva-
tives of somatic cells generated by cellular reprogram-
ming. But exactly this implausible conclusion identifies
the moral implications of reprogramming research: if
through the manipulation of selected genes a differenti-
ated cell can be coaxed back into a totipotent state, this
transient state will have lost any intrinsic property and
hence any possible moral claim. It will just be one of
many possible states in which a cell can exist, within or
outside the human body.
From Proof-of-Principle to Translation:
Who Is Doing What?
Basic scientists easily get excited about the potential ben-
efits of their work for biomedicine. Yet it remains a long
way from a beating cardiomyocyte generated in a cell cul-
ture dish to a standardized treatment of heart disease.
One important question addressed at the meeting was
how to plan first clinical trials. Key prerequisites for clinical
applications are safety and efficacy. A central issue asso-
ciated in particular with the use of ESC-derived somatic
cells is to transplant them at high purity and devoid of re-maining undifferentiated cells, which may otherwise lead
to tumor formation. Moreover, standardized procedures
based on good manufacturing practice (GMP) are re-
quired for scale-up and differentiation of stem cells in
a clinical context. Most of the currently existing human
ES cell lines were generated in a nonstandardized man-
ner, in some cases using procedures known to promote
acquisition of genetic aberrations. Outi Hovatta, from the
Karolinska Institute, pointed out that the stem cell field
needs to move toward the generation of additional ES
cell lines under standardized conditions. The establish-
ment of stem cell banks would enlarge the spectrum of
available haplotypes and thus facilitate donor-host match-
ing and reduce the risk of transplant rejection.
Once the scientific and basic technical requirements for
donor cell generation are sorted out, there will remain
a need to actually engage in product development and
distribution. GLP and GMP facilities, automatic systems
to scale-up stem cell production, stem cell banking, and
safety testing do not fall within the realm of academic re-
search. These tasks can only be tackled in joint efforts
with the commercial sector. At this stage, translation can
be further enhanced by close association of biotech in-
dustry, academic research labs, and university hospitals,
as it is already the case in Sweden. Lars Wahlberg, from
NsGene A/S, stressed that access to academic gene
and cell therapy facilities may significantly ease the imple-
mentation of clinical trials. On the other hand, Greg Stew-
art, from Medtronic, Inc., pointed out that investing in SC
production is extremely expensive, and the profit of a com-
pany is unlikely to be satisfactory when compared to the
amount of money and effort required to build up the busi-
ness. One question emanating from this controversy was
whether temporary governmental support could acceler-
ate this process and provide incentives for biotech indus-
try to take on such high-risk endeavors. This issue be-
comes particularly relevant for treatment of orphan
diseases, in which costs for research and development
vastly exceed potential profits.
Ethics’ Paralyzing Grip on Commercialization
Many at the meeting agreed that usually an ambivalent
attitude results when industry faces clinical applications.
Whereas biomedical stem cell research is considered
a high-ranking goal, commercialization generally is met
with skepticism. And while academic stem cell research
enjoys increasing support throughout Europe (with the no-
table exceptions of Germany and Italy), the potential for
commercial use has become the true battlefield of stem
cell critics. If parts of society see it as morally problematic
to use embryos for research, how much more problematic
is this process when substantial commercial revenue
comes into play? Wherever such fundamental questions
of moral and human value are raised, the ensuing polariza-
tion tends to become a minefield for politicians and deci-
sion makers. Commonly, the best way to survive in a mine-
field is not to move. But as several contributors to the
Berlin meeting underscored, not moving also has a cost:
the stigmatizing attitude toward commercial stem cellCell Stem Cell 1, August 2007 ª2007 Elsevier Inc. 155
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for developing biomedical applications. And if one is seri-
ous about the ethical appraisal of stem cell research, one
should at the very least also consider the ethical costs as-
sociated with delaying the fruition of stem cell research’s
potential benefits.
The situation is particularly difficult when voters ask for
both technological leadership and conservation of tradi-
tional views. The Bush administration has managed to
navigate this conflict with the de facto creation of two
parallel universes, a straightforward task given the stand-
ing of free enterprise in American tradition: while federally
funded hESC research is tightly regulated and restricted to
cell lines generated before August 2001, the private sector
is practically not subject to any restrictions.
One of the most controversial topics in the field of trans-
lational stem cell research is patenting, as pointed out by
Aurora Plomer from the University of Sheffield. In Europe,
research on human ES cells is accepted, yet in most cases
patents are not. For instance, in Germany, academic re-
search on human ES cells is permitted, and public funding
bodies explicitly demand researchers to assess patent-
ability of their results prior to publication. Yet, a recent
lawsuit challenging a patent for the derivation of neural
precursor cells from ES cells that was originally granted
to Oliver Bru¨stle in 1999 is a tough reminder of the current
contradiction in this area of regulation. As Clara Sattler
(Max Planck Institute for Intellectual Property, Competi-
tion, and Tax Law, Munich) explained, the German federal
patent court ruled that, despite the ethically high-ranking
goals pursued, the patent is immoral and against the ‘‘or-
dre public’’ due to the embryonic origin of the cells. In line
with the previous considerations, several commentators
at the Berlin meeting questioned the very notion of ordre
public as well as the peculiar arrangement whereby patent
courts are entrusted with the authority to determine, on
behalf of society, what ultimately constitutes ordre public.
On a practical level, then, countries like Germany will con-
tinue to lose ground to countries that forbid patents on the
actual derivation of ES cells, but not on essential aspects
of their subsequent manipulation (as is the case of the
Bru¨stle patent). Thus, Goran Hermeren stressed, the risk
of patenting abroad discoveries made in such European
countries, as was already the case for several technolog-
ical advances, persists.
International Regulations Needed
to Facilitate Synergy
One of the most remarkable observations a visitor of the
Berlin meeting could be confronted with was the pro-
nounced international heterogeneity in stem cell legisla-
tion. Projects that are perfectly legal in Sweden and the
UK can draw a 3 year prison sentence in Germany. This
incongruency creates a plethora of problems for interna-
tional collaboration. Despite common funding by the 6th
and 7th frameworks of the EC, scientists within Europe
cannot freely exchange personnel and cell lines. Re-
searchers from countries with very restrictive legislation,156 Cell Stem Cell 1, August 2007 ª2007 Elsevier Inc.such as Germany, might even become liable by taking
on coordinating positions within European networks
comprising institutions that generate their own hESC
lines. The meeting made evident that these problems
severely hamper international collaboration and synergy
development, which are instrumental in a multidisciplinary
field such as stem cell research. There is an increasing
awareness that European heterogeneity in stem cell
politics is about to slow the development of stem cell-
based biomedical applications and further impede the
competitiveness of Europe in global stem cell science.
Yet, in the Berlin meeting, these issues were not only dis-
cussed from the point of view of global competition. There
was also intense discussion about the ethical implications
of individual countries’ stance that de facto withholds the
development of novel biomedical applications from their
populations. The question of whether such restrictive
legislations will be able to live up to this ring fencing
once new stem cell-based treatments become available
remains for the most unsolved.
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